MassDevice podcast: Hamilton Thorne CEO Meg Spencer
April 15, 2011 by Christian Holland
Meg Spencer, CEO of laser manufacturer Hamilton Thorne Ltd., on how the company stays on the cutting edge of life science technology and its footprint in stem cells and regenerative medicine.
Laser-based lab equipment maker Hamilton Thorne Inc. (CVE:HTL) derives a major part of its revenues from the life sciences R&D market. CEO Meg Spencer says that requires the company to surf the leading edge of several life science research waves, including stem cells and regenerative medicine.
The Beverly, Mass.-based company looks to help solve some of the problems scientists encounter as they develop their research on stem cells into regenerative medicine techniques. Those often involve the growth of millions — or even billions — of cells, so anything that can accelerate or automate that process is vital to innovation in the space.
News Well, MassDevice Q&A, Laboratory Instruments/Laboratory Supplies, Regenerative Medicine, Stem Cells
Permalink
FDA Database Search
RECENT BLOG POSTS
- Funding R&D: High prices, overuse a failed strategy
- FDA's role in promoting women's health
- New partnership to boost use of GMDN codes for medical devices
- FDA's modern "Corps of Discovery" in China
- Consumers lose in latest FDA user fee bill; COI restraints disappear
- Gamification
- Cool technology of the week
- A new day: Interim thoughts on the 2012 Heart Rhythm Society scientific sessions
- When a child loses milestones, consider sleep EEG studies
- Red or blue pill for payment reform? Both won't work
Features
